Combinatorial assessment of ctDNA release and mutational burden predicts anti-PD(L)1 therapy outcome in nonsmall-cell lung cancer
Clin Transl Med
.
2020 Jan;10(1):331-336.
doi: 10.1002/ctm2.8.
Authors
Wenfeng Fang
1
,
Yuxiang Ma
1
,
Jiani C Yin
2
,
Huaqiang Zhou
1
,
Fufeng Wang
2
,
Hua Bao
3
,
Ao Wang
3
,
Xue Wu
3
,
Shaodong Hong
1
,
Yunpeng Yang
1
,
Yan Huang
1
,
Hongyun Zhao
1
,
Yang W Shao
2
4
,
Li Zhang
1
Affiliations
1
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
2
Nanjing Geneseeq Technology Inc., Nanjing, China.
3
Department of Medical, Geneseeq Technology Inc., Toronto, Ontario, Canada.
4
School of Public Health, Nanjing Medical University, Nanjing, China.
PMID:
32508057
PMCID:
PMC7240844
DOI:
10.1002/ctm2.8
No abstract available
Grants and funding
2016YFC0905500/National Key R&D Program of China
2016YFC0905503/National Key R&D Program of China
2017B020227001/Science and Technology Program of Guangdong
81772476/Chinese National Natural Science Foundation
81602005/Chinese National Natural Science Foundation
81872499/Chinese National Natural Science Foundation
16zxyc04/Outstanding Young Talents Program of Sun Yat-sen University Cancer Center
17ykpy81/Central Basic Scientific Research Fund for Colleges-Young Teacher Training Program of Sun Yat-sen University